CCNT2

CCNT2 (Cyclin T2) is the regulatory cyclin subunit of P-TEFb that partners with CDK9 in a mutually exclusive manner relative to Cyclin T1, conferring DRB-sensitive kinase activity that phosphorylates the RNA Pol II CTD to drive transcriptional elongation (PMID:9499409). The majority of cellular CCNT2-containing P-TEFb is held inactive in a 7SK snRNA/HEXIM1 complex, from which it is released upon transcriptional stress to stimulate elongation; this equilibrium is regulated by Brd4 and MED26-mediated recruitment to chromatin (PMID:11713533, PMID:12832472, PMID:16109376, PMID:21729782). Genetic ablation of Ccnt2 in mice causes embryonic lethality, and CCNT2 regulates non-redundant gene sets relative to Cyclin T1, including control of VEGFA alternative splicing through modulation of Pol II elongation rate, adipogenic gene expression, oligodendrocyte differentiation, and cell cycle progression in leukemia cells (PMID:19364821, PMID:34316716, PMID:27627980, PMID:26843650, PMID:28409330).

1. 1998 High

   Identification of Cyclin T2a and T2b as alternative splice-derived regulatory subunits of P-TEFb established that CDK9 partners with multiple cyclins to drive transcription elongation, resolving the molecular composition of the complex.

   Evidence Immunoprecipitation, recombinant protein reconstitution in Sf9 cells, in vitro kinase and transcription elongation assays in HeLa nuclear extracts

   PMID:9499409

   Open questions at the time

   • Whether CycT2a and CycT2b have distinct substrate specificities or gene targets was not addressed
   • In vivo functional distinction between CycT1- and CycT2-containing P-TEFb remained unknown
2. 2001 High

   Discovery that 7SK snRNA sequesters >50% of P-TEFb (including CycT2-containing forms) into inactive high-molecular-weight complexes revealed a major regulatory layer controlling elongation capacity, with stress-induced release as a feedback mechanism.

   Evidence Sucrose gradient sedimentation, co-immunoprecipitation, in vitro kinase assays with chemical inhibitor and UV treatment in HeLa cells

   PMID:11713533

   Open questions at the time

   • The protein factor(s) mediating P-TEFb inhibition within the 7SK complex had not yet been identified
   • The stoichiometry of CycT2-containing vs CycT1-containing inactive complexes was not determined
3. 2003 High

   Identification of HEXIM1 as the direct inhibitory protein within the 7SK/P-TEFb complex, binding the cyclin homology region of both CycT1 and CycT2, resolved how 7SK-dependent inhibition is executed at the molecular level.

   Evidence Yeast two-hybrid, co-immunoprecipitation of endogenous and transfected complexes

   PMID:12832472

   Open questions at the time

   • The structural basis of HEXIM1–Cyclin T interaction was not resolved
   • Whether HEXIM1 preferentially inhibits CycT1- vs CycT2-containing P-TEFb was not tested
4. 2004 High

   In vitro reconstitution demonstrated that 7SK RNA is required to convert HEXIM1 into an active P-TEFb inhibitor, mapping the RNA-recognition and P-TEFb-binding domains of HEXIM1, thereby defining the molecular logic of the inhibitory switch.

   Evidence Reconstitution with purified components, gel-shift assays, GST pull-down, point mutagenesis

   PMID:15201869

   Open questions at the time

   • Whether CycT2-specific sequences differentially modulate HEXIM1 affinity was not examined
   • Signals that trigger 7SK release in vivo remained incompletely defined
5. 2005 Medium

   Brd4 was shown to recruit the active (7SK/HEXIM1-free) form of P-TEFb to acetylated chromatin and stimulate CTD phosphorylation, establishing a recruitment mechanism linking histone acetylation to transcription elongation.

   Evidence Affinity purification-mass spectrometry, co-immunoprecipitation, ChIP, siRNA knockdown, transcription assays

   PMID:16109376

   Open questions at the time

   • Whether Brd4 preferentially recruits CycT1- vs CycT2-containing P-TEFb was not resolved
   • The relative contribution of Brd4 vs other recruiters (e.g., MED26, Aire) at different loci was unknown
6. 2008 High

   Determination of the crystal structure of free Cyclin T2 and the CDK9/CycT1 complex revealed C-type cyclin structural features and a distinctive CDK–cyclin interface rotation, providing a structural framework for understanding P-TEFb assembly and regulation.

   Evidence X-ray crystallography, in vitro kinase assays, mutagenesis

   PMID:18566585

   Open questions at the time

   • A co-crystal of CDK9 bound to CycT2 (rather than CycT1) was not obtained
   • How the structural differences between CycT1 and CycT2 affect substrate selection remained unknown
7. 2009 High

   Genetic ablation of Ccnt2 in mice demonstrated embryonic lethality and gene-expression profiling after knockdown in ES cells showed CycT1 and CycT2 regulate non-overlapping gene sets, establishing that the two P-TEFb cyclins are functionally non-redundant in vivo.

   Evidence Gene trap mutagenesis in mice, beta-galactosidase expression analysis, siRNA knockdown in embryonic stem cells, gene expression profiling

   PMID:19364821

   Open questions at the time

   • The embryonic stage and developmental process at which lethality occurs was not precisely defined
   • Molecular basis of target gene selectivity between CycT1 and CycT2 was not determined
8. 2011 Medium

   MED26 was identified as a Mediator subunit that acts as a molecular switch exchanging TFIID for SEC/P-TEFb at promoters, revealing a Mediator-dependent pathway for transition from initiation to elongation.

   Evidence Affinity purification-mass spectrometry, co-immunoprecipitation, ChIP, transcription assays

   PMID:21729782

   Open questions at the time

   • Direct involvement of CycT2-containing P-TEFb in MED26-dependent recruitment was inferred but not specifically demonstrated
   • Whether MED26 acts genome-wide or at specific promoter classes was not resolved
9. 2014 Medium

   An RNAi screen in thymic epithelial cells identified CCNT2 as a functional collaborator of Aire in driving ectopic autoantigen gene expression, with HNRNPL mediating 7SK/P-TEFb delivery to Aire-containing complexes — extending P-TEFb function to immune tolerance.

   Evidence Genome-scale lentiviral shRNA screen, RNA co-immunoprecipitation, lentigenic knockdown mice, flavopiridol treatment

   PMID:24434558

   Open questions at the time

   • Whether CycT2-containing P-TEFb is specifically preferred over CycT1 in Aire-dependent transcription was not tested
   • The in vivo autoimmune phenotype upon CycT2-specific depletion in thymic epithelium was not assessed
10. 2016 Medium

    CCNT2 was identified as a direct miR-297c-5p target controlling oligodendrocyte precursor differentiation and a miR-192 target promoting cell cycle progression in AML cells, demonstrating cell-type-specific P-TEFb functions regulated at the post-transcriptional level.

    Evidence Luciferase reporter assays, siRNA knockdown, lentiviral transduction, flow cytometry, rescue experiments in OPCs and NB4/HL-60 leukemia cells

    PMID:26843650 PMID:28409330

    Open questions at the time

    • Whether miRNA-mediated CycT2 regulation shifts the CycT1/CycT2 ratio and alters P-TEFb target selectivity was not explored
    • In vivo relevance of these miRNA–CCNT2 axes in myelination or leukemogenesis was not established
11. 2021 Medium

    CCNT2 was shown to occupy both the promoter and a distal enhancer of VEGFA and to control alternative splicing by modulating Pol II elongation rate, directly linking P-TEFb elongation kinetics to co-transcriptional splicing decisions.

    Evidence ChIP, siRNA silencing, RNA-seq and RT-PCR splice isoform analysis, RNAPII elongation rate measurement

    PMID:34316716

    Open questions at the time

    • Whether CCNT2-dependent splicing regulation extends genome-wide or is locus-specific was not determined
    • The contribution of enhancer-bound CCNT2 versus promoter-bound CCNT2 to splicing regulation was not separated

• A major unresolved question is what determines CycT2 versus CycT1 target gene selectivity — whether it reflects differential chromatin recruitment, distinct protein interaction surfaces, or tissue-specific expression ratios.
• No genome-wide CycT2 ChIP-seq in comparison with CycT1 has been reported
• Structural basis for any CycT2-specific protein interactions remains unknown
• Conditional tissue-specific knockouts of CycT2 have not been characterized